ANRS, Emerging Infectious Diseases: Hepatitis B trials

The registry lists 13 Hepatitis B studies with ANRS, Emerging Infectious Diseases as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2Phase 3 2Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• "HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"RecruitingNCT07054359Not applicable
• National Cohort of Patients Co-infected with Hepatitis B and Delta VirusesRecruitingNCT04166266
• Health and Migration Trajectories of Housekeepers in BamakoCompletedNCT05472051
• ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC DiscontinuationStatus unknownNCT05045261Phase 2
• Sexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'IvoireStatus unknownNCT03985085Not applicable
• Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, SenegalCompletedNCT03215732
• Tenofovir As Prevention Of Hepatitis b Mother-to-child TransmissionStatus unknownNCT02937779Phase 4
• Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-FranceCompletedNCT02566148
• Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B VaccinationCompletedNCT02323308
• Therapeutic Option for Hepatitis B and C: a French CohortStatus unknownNCT01953458
• A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis BStatus unknownNCT01172392Phase 3
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)CompletedNCT00670839Phase 3